Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Chinese Journal of Clinical Laboratory Science ; (12): 102-105, 2018.
Article in Chinese | WPRIM | ID: wpr-694812


Objective To investigate the regulatory effects of miR-145 on MMP2 expression in lung adenocarcinoma cell A549 and the mechanism involved in the regulation.Methods Lipofectamine 2000 reagent-mediated miR-145 mimic or mimic negative control (NC) was transiently transfected into lung adenocarcinoma cell A549.The expression levels of miR-145 were determined by RT-PCR.MMP2 and β-catenin expression was detected by western blot.Lithium chloride (LiC1),the activator of Wnt/β-catenin pathway,and miR-145 mimic co-processed to act on A549 cells,then the expressions of MMP2 and β-catenin were detected by Western blot.Results The results of RT-PCR showed that the difference of miR-145 in miR-145 mimic group,NC group and blank group was statistically significant(F =296.30,P <0.05).western blot showed that the expression levels of MMP2 and nucleus β-catenin were significantly downregulated in miR-145 overexpression group compared with the control (q =8.98,26.59,all P < 0.05).Additionally,the effects of co-processing factors on the cells showed that the activation of wnt/β-catenin pathway reversed the inhibition of miR-145 on MMP2 expression(q =49.47,P < 0.05).Conclusion miR-145 may downregulate MMP2 expression through inhibition of Wnt/β-catenin pathway activity in lung adenocarcinoma cell A549.

Journal of Medical Postgraduates ; (12): 1276-1279, 2015.
Article in Chinese | WPRIM | ID: wpr-484115


Objective Plasma circulating DNA can be em-ployed in place of bone marrow examination for the auxiliary diagnosis of leukemia.This study aimed to explore the clinical application of the plasma DNA level in evaluating the effect of chemotherapy on chronic leukemia. Methods We collected blood samples from 52 patients with chronic myelogenous leukemia (CML) (33 in the chronic phase, 7 in the acceleration phase, and 12 in the blast phase) , 85 with chron-ic lymphocytic leukemia (CLL) (28 with complete remission, 27 with partial remission, and 30 with no remission), 4 patients with hairy cell leukemia (HCL), and 80 healthy subjects.We simultaneously obtained plasma DNA and recombinant plasmid DNA using the BI-LATEST DNA Kit and examined the human β-actin gene and the level of plasmid DNA by real-time quantitative PCR. Results Before chemotherapy, the median value of plasma DNA was 149.46(30.63-496.91)ng/ml in the CML and 101.54(69.10-258.14) ng/ml in the CLL patients, both significantly higher than in the healthy controls (19.05[12.67-25.92]ng/ml) (P<0.01).After chemotherapy, the plasma DNA level of the CML patients was remarkably decreased, but still higher than that of the controls ( P<0.01).The CML patients in the chronic phase showed a markedly higher level of plasma DNA (302.89[93.33-541.52]ng/ml) than those in the blast phase (43.19[23.54-70.03]ng/ml) and acceleration phase (28.11[16.21-92.07]ng/ml) (P<0.05).The CLL patients with CR exhibited a significantly lower level of plasma DNA (24.29[14.64-30.74]ng/ml) than those with PR (106.88 [96.23-143.25]ng/ml) and NR (460.73[284.57-653.38〗ng/ml) (P<0.01), but all dramatically higher than that of the healthy controls (P<0.01) Conclusion The quantification of plasma DNA has a clinical application value in evaluating the effect of chemo-therapy on chronic leukemia.